Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
This article was originally published in The Tan Sheet
Executive Summary
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says
You may also be interested in...
FDA Works To Fill Advisory Panel Seats While Tightening Conflict Rules
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
FDA Works To Fill Advisory Panel Seats While Tightening Conflict Rules
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
FDA Works To Fill Advisory Panel Seats While Tightening Conflict Rules
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats